Apriem Advisors boosted its position in shares of Clorox Co (NYSE:CLX) by 39.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 33,085 shares of the company’s stock after purchasing an additional 9,347 shares during the quarter. Clorox makes up 1.8% of Apriem Advisors’ portfolio, making the stock its 18th biggest holding. Apriem Advisors’ holdings in Clorox were worth $5,100,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of CLX. Advisory Services Network LLC lifted its position in shares of Clorox by 2.0% in the fourth quarter. Advisory Services Network LLC now owns 7,752 shares of the company’s stock valued at $1,194,000 after acquiring an additional 155 shares in the last quarter. HRT Financial LLC purchased a new stake in shares of Clorox in the fourth quarter valued at $237,000. Millennium Management LLC lifted its position in shares of Clorox by 323.7% in the fourth quarter. Millennium Management LLC now owns 6,643 shares of the company’s stock valued at $1,024,000 after acquiring an additional 9,613 shares in the last quarter. Merit Financial Group LLC purchased a new stake in shares of Clorox in the fourth quarter valued at $215,000. Finally, Phocas Financial Corp. purchased a new stake in shares of Clorox in the fourth quarter valued at $193,000. Institutional investors own 76.80% of the company’s stock.
Several brokerages have recently issued reports on CLX. Zacks Investment Research downgraded Clorox from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Credit Suisse Group initiated coverage on Clorox in a research note on Wednesday, March 6th. They issued an “outperform” rating and a $172.00 target price for the company. Wells Fargo & Co reiterated a “hold” rating and issued a $157.00 target price on shares of Clorox in a research note on Thursday, February 21st. Barclays reiterated a “hold” rating and issued a $142.00 target price on shares of Clorox in a research note on Wednesday, February 6th. Finally, Citigroup set a $171.00 target price on Clorox and gave the company a “hold” rating in a research note on Tuesday, February 5th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $152.15.
Clorox (NYSE:CLX) last announced its quarterly earnings results on Monday, February 4th. The company reported $1.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.08. The company had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.47 billion. Clorox had a return on equity of 105.97% and a net margin of 12.65%. The firm’s revenue was up 4.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.77 earnings per share. Research analysts predict that Clorox Co will post 6.33 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Wednesday, April 24th will be paid a dividend of $0.96 per share. The ex-dividend date is Tuesday, April 23rd. This represents a $3.84 annualized dividend and a yield of 2.43%. Clorox’s dividend payout ratio is presently 61.34%.
In other Clorox news, SVP Andrew J. Mowery sold 5,340 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $156.44, for a total transaction of $835,389.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Matthew T. Laszlo sold 10,585 shares of the company’s stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total value of $1,628,925.65. Following the sale, the senior vice president now owns 17,994 shares of the company’s stock, valued at $2,769,096.66. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/4249031/clorox-co-clx-shares-bought-by-apriem-advisors.html.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
See Also: Should You Consider an Index Fund?
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.